欧洲药物局加速评估的执行情况
Vittorio Del Grosso1, Martina Perini1, Giorgio Casilli2
1Department of Pharmaceutical Sciences, Università del Piemonte Orientale "Amedeo Avogadro", Novara, Italy.
British journal of clinical pharmacology
|January 10, 2025
概括
少数药物使用欧洲药物局 (EMA) 的加速评估 (AA) 途径. 虽然这些药物在卫生技术评估 (HTA) 机构的审查速度更快,但它们并不总是显示出显著的治疗价值.
科学领域:
- 药品监管法规 药品监管法规 药品监管法规
- 卫生技术评估 卫生技术评估
- 药物批准过程 药物批准过程
背景情况:
- 欧洲药物署 (EMA) 提供了一种加速评估 (AA) 途径,以优先考虑药物批准.
- 在批准后,药物经过国家机构的健康技术评估 (HTA),以确定患者的可访问性和治疗价值 (ATV).
研究的目的:
- 通过EMA的加速评估 (AA) 途径评估药物的特征.
- 仔细审查这些优先级药物的随后的HTA程序和ATV评估.
主要方法:
- 对EMA授权药物的监管文件 (2019-2021) 的分析,以建立监管数据库.
- 从三个国家HTA机构 (AIFA,HAS,G-BA) 提取EMA加速途径候选人的数据,将其提取到第二个数据库中.
主要成果:
- 在164种授权药物中,只有12种药物通过AA途径进行了评估,这比标准评估 (364天) 时间 (189天) 短得多.
- 小化学实体不太可能使用AA,而生物制品和PRIME计划药物更有可能使用AA. AA增加了特殊情况授权的可能性.
- 这12种产品获得了更快的HTA审查,但与现有替代品相比,它们并没有始终显示出主要的ATV.
结论:
- 加速评估途径被少数药品使用.
- 虽然HTA机构加速对AA评估药物的审查,但与替代品相比,重要的临床优势并不总是被认可.
相关概念视频
Pharmacovigilance
771
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
771
Preclinical Development: Overview
4.2K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.2K
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K
Drug Control Governance: Regulatory Bodies and Their Impact
139
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
139
Bioequivalence: Overview
918
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
918


